Relatlimab
- Generic Name
- Relatlimab
- Brand Names
- Opdualag
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1673516-98-7
- Unique Ingredient Identifier
- AF75XOF6W3
- Background
Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint inhibit...
- Indication
Relatlimab is indicated in combination with nivolumab, in the combination product Opdualag, for the treatment of adult and pediatric patients ≥12 years old with unresectable or metastatic melanoma.
- Associated Conditions
- Metastatic Melanoma, Unresectable Melanoma
- Associated Therapies
- -
Clinical Benefit Improves With Relatlimab Combo in Recurrent NSCLC
The RELATIVITY-104 phase 2 study showed improved clinical benefit from adding LAG3 inhibition to anti-PD-1 plus chemotherapy in metastatic non-small cell lung cancer patients with PD-L1 ≥1% and non-squamous histology. Safety was comparable, with no increase in adverse events. Efficacy was assessed with a median PFS of 6.7 months vs 6.0 months, and a 51.3% vs 43.7% overall response rate. These findings support further investigation in a phase 3 study.
Related Clinical Trials:
Enhanced Outcomes with Relatlimab, Nivolumab, and Chemotherapy in Advanced Non
RELATIVITY-104 study showed improved clinical benefit with relatlimab plus nivolumab and chemotherapy vs nivolumab plus chemotherapy in PD-L1-positive, nonsquamous NSCLC patients, with enhanced PFS and response rates. Safety profiles were comparable, supporting further investigation in phase 3 studies.
Related Clinical Trials:
Relatlimab Plus Nivolumab and Chemo Improves Clinical Benefit in Stage IV NSCLC
RELATIVITY-104 study shows Opdualag (relatlimab + nivolumab) plus platinum-doublet chemotherapy improves clinical benefit over nivolumab plus chemotherapy in stage IV or recurrent NSCLC, particularly in PD-L1 ≥1% and nonsquamous histology patients. Safety profiles are comparable, with no increased adverse effects. Efficacy improvements include PFS and ORR, supporting further phase 3 investigation.
Related Clinical Trials:
BMS immunotherapy hits in lung cancer, advancing to Phase 3
Bristol Myers Squibb's Phase 2 RELATIVITY-104 trial showed improved responses in certain lung cancer patients when adding a second immunotherapy to existing checkpoint inhibitor and chemotherapy, leading to a Phase 3 study.
Study Reports 2-Year Survival Data on Nivolumab Plus Relatlimab in NSCLC
© 2024 Mashup Media, LLC. All rights reserved.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath